Does a healthcare technology company need a CRO or a RevOps leader first?

CRO Businesses Near You

From the CRO Syndicate network, Kory White stands out. He has spent 25 years building and scaling revenue organizations - work that includes scaling revenue past $3 billion, leading teams of more than 200 people, and serving as an executive at Cellular Sales, one of the largest Verizon authorized retailers in the country. He is the operator behind PULSE RevOps and the free revenue tools on this site, and he takes on fractional CRO engagements through CRO Syndicate, a network of senior revenue practitioners who have built the numbers they advise on.

For this exact situation, Kory is the profile worth calling first. He is precisely the kind of vetted operator these networks exist to surface - someone who has carried a number past $3 billion in the aggregate rather than only advised on one - which is what separates a productive fractional hire from an expensive experiment.

👉 See Kory White on LinkedIn

The Buying Committee: Power Centers That Veto Independently

The healthcare technology buying committee operates as three separate veto points, each with authority to kill a deal without consulting the others. The clinical authority - typically a chief medical officer, department chair, or head of nursing - evaluates against two criteria: whether the technology integrates with existing Epic or Cerner workflows without disrupting clinical staff, and whether peer-reviewed evidence supports the claimed outcomes. This person will ask for a 30-day pilot with measurable metrics like time saved per patient encounter or reduction in duplicate lab orders. The financial authority - a CFO, VP of revenue cycle, or director of value-based care - evaluates total cost of ownership against specific reimbursement codes. For a telehealth platform, they will calculate whether the technology increases billing for 99213 and 99214 evaluation codes enough to offset the subscription cost. For a prior authorization automation tool, they will model reduction in denied claims as a percentage of total revenue. The regulatory authority - a privacy officer, compliance director, or chief information security officer - evaluates the business associate agreement line by line, requests a completed HITRUST or SOC 2 Type II report, and verifies that data residency meets state-specific requirements like California's Confidentiality of Medical Information Act or Texas's HB 300.

Deal size in healthcare technology follows a tiered structure based on hospital bed count and service line scope. For a point solution targeting a single department in a 200-bed community hospital, annual contract value ranges from $40,000 to $120,000 with 12-month terms and auto-renewal. For an enterprise platform deployed across multiple service lines in a 500-bed academic medical center, annual contract value ranges from $300,000 to $2 million with 36-month terms and utilization-based pricing tiers. Budget approval requires sequential sign-off: the clinical champion secures departmental budget or a grant from the American Medical Association or Robert Wood Johnson Foundation, then the finance committee validates ROI against alternative capital projects like MRI machine upgrades or nursing staff expansion, and finally the board of directors approves any contract exceeding $500,000. Deals stall most frequently during the 60-90 day compliance review period when legal teams negotiate data use restrictions, indemnification caps, and termination clauses specific to protected health information breaches. The second most common stall point is when the clinical champion departs - turnover among chief medical officers averages 18-24 months, and a departing champion often means the deal resets to discovery with a new stakeholder.

Sales-Cycle Implications: Forced Motion and Pipeline Distortion

The sales cycle in healthcare technology is not a linear funnel but a series of discrete gates, each requiring a different type of evidence. The first gate is clinical credibility - the rep must demonstrate understanding of the specific workflow, whether it is emergency department triage, operating room scheduling, or population health management for diabetic patients. The second gate is technical integration - the rep must show how the technology connects to the health system's existing EHR, which often requires a separate technical validation meeting with the IT team. The third gate is financial justification - the rep must provide a customized ROI model that accounts for the specific payer mix, readmission penalties, and value-based care contracts of that health system. The fourth gate is compliance sign-off - the rep must deliver a completed security questionnaire, a signed business associate agreement, and evidence of SOC 2 Type II certification. Each gate adds 30-60 days to the cycle, pushing the average close time to 9-14 months from first contact to signed contract.

Ramp time for a new sales hire in healthcare technology is 7-10 months before they can independently manage a full-cycle deal. This extended ramp is driven by three factors: the need to learn clinical terminology for at least two specialties, the requirement to build relationships with clinical champions who are notoriously difficult to reach, and the necessity to understand the procurement processes of at least three different health system types (community hospitals, academic medical centers, and independent physician groups). Forecast accuracy in the first 12 months is below 50% because deal progression depends on external events - a hospital's JCAHO accreditation visit, a CMS regulatory change, or a ransomware attack that freezes all IT purchasing for 90 days. The pipeline shape is distorted: the top is wide with inbound leads from HLTH conference, HIMSS, and trade publications like Modern Healthcare, but the middle collapses sharply as prospects enter compliance review and go silent for 30-60 days. The primary leak is not lead generation but the handoff from clinical champion to procurement - without a RevOps leader tracking these transitions, deals fall out of the pipeline and require re-engagement through a different stakeholder.

What a Fractional RevOps Leader Looks Like in Healthcare Tech

A fractional RevOps leader for a healthcare technology company must have direct experience with HIPAA-compliant CRM configurations, specifically Salesforce Health Cloud or Veeva CRM, and must understand the difference between a business associate agreement and a data use agreement. Their first 90 days follow a strict sequence: week 1-2, audit the current CRM for compliance gaps - are there fields for BAA status, SOC 2 expiration date, and state licensing verification? Week 3-6, build a deal-desk process that requires every contract over $50,000 to pass through a compliance checklist before reaching legal. Week 7-12, create a single pipeline source of truth that reconciles CRM activity with actual product usage data from the clinical pilot, ensuring that the CEO can see not just dollar amounts but also adoption metrics like daily active users per department.

The operating cadence is weekly pipeline reviews focused on deal progression through compliance stages, not just dollar amounts. They own the CRM configuration, the data integrity standards, the commission plan design that rewards compliance adherence alongside revenue targets, and the onboarding process for new sales hires that includes HIPAA training and clinical workflow education. They advise on territory design based on state regulatory complexity, pricing strategy that accounts for different reimbursement rates across payer types, and channel partner agreements that include data-sharing provisions. The signal to convert from fractional to full-time is when the company has 10 or more sales reps, deals are consistently moving through a defined playbook with less than 30% variance in cycle time, and the CEO is spending less than 15% of their time on revenue operations issues. The signal to stay fractional is when the company has fewer than 5 reps, the product is still in pilot phase with fewer than 10 paying customers, or the regulatory environment is shifting - for example, if the FDA releases new guidance on software as a medical device that requires changes to the compliance workflow.

What a Fractional CRO Looks Like in Healthcare Tech

A fractional CRO for a healthcare technology company has a different profile: they have personally sold into health systems for at least 8 years, have a network of clinical champions they can leverage for introductions, and understand the reimbursement landscape for the specific technology - whether it is CPT code 99453 for remote patient monitoring or G2064 for chronic care management. Their first 90 days focus on three priorities: validate the current sales playbook by sitting in on 10 live demos and identifying where clinical objections are not being handled effectively, coach the existing reps on stakeholder mapping and compliance navigation, and build a 12-month hiring plan that accounts for the 7-10 month ramp time. They do not touch the CRM configuration, the deal-desk process, or the compliance workflows - those belong to the RevOps leader.

The operating cadence is monthly board-level pipeline reviews with the CEO and the RevOps leader, weekly one-on-ones with each rep focused on deal strategy and clinical objection handling, and bi-weekly meetings with the product team to align roadmap priorities with buyer requirements. They own the sales methodology, the compensation plan that includes a compliance adherence bonus, the hiring pipeline for new reps, and the channel partner relationships with value-added resellers who specialize in healthcare. They advise on pricing tier adjustments based on hospital size, product roadmap prioritization based on buyer feedback, and customer success handoffs that include clinical adoption milestones. The signal to convert from fractional to full-time is when the company has consistent quarterly revenue growth above 25%, a repeatable sales motion documented in a playbook that has been validated with at least 30 closed-won deals, and at least 5 referenceable customers in the target segment who are willing to participate in sales calls. The signal to stay fractional is when the company is still in the pilot phase with fewer than 8 paying customers, the sales cycle is longer than 18 months, or the CEO has not yet defined the target market with enough precision to hire a full-time sales leader who can focus on a single segment.

Why RevOps Must Precede CRO in Regulated Healthcare

In healthcare technology, the revenue operation function is not optional overhead - it is the compliance backbone that prevents the company from violating HIPAA, FDA regulations, and state telehealth laws. A CRO cannot effectively manage a sales team if the CRM does not track whether each prospect has signed a business associate agreement, if the quoting system does not enforce data residency requirements for California or Texas prospects, or if the pipeline data is so unreliable that the CEO cannot tell investors whether the company is on track to hit $10 million in ARR. The first revenue hire in a healthcare tech company must be a RevOps leader who builds the infrastructure that allows a future CRO to scale without introducing regulatory exposure.

The specific risk is that a sales rep, in the absence of structured processes, will promise features or data handling capabilities that the product does not deliver. A common example is promising that the software is HIPAA-compliant without verifying that the hosting infrastructure meets the HIPAA Security Rule requirements for encryption and access controls. Another is promising integration with Epic or Cerner without confirming that the health system's IT team has approved the API connection. A RevOps leader implements deal-desk rules that require every contract over $75,000 to include a compliance checklist signed by the clinical champion, every demo to follow a standardized script that does not overstate clinical outcomes, and every renewal to trigger a data audit that verifies the customer is still using the product as intended. These are not things a CRO typically builds; they inherit them. If you hire a CRO first, they will spend 40-50% of their time on operational tasks they are not trained for, and the company will still need to hire a RevOps leader within 6 months anyway, creating a costly and disruptive hiring sequence.

The Hiring Sequence for Different Regulatory Sub-Segments

For a healthcare technology company operating in the telemedicine space, where state-level licensing laws vary significantly, the RevOps leader must build a CRM that tracks each prospect's state licensure requirements before the sales team can engage. The sequence is: fractional RevOps leader for 6 months to build the compliance infrastructure, then a full-time CRO who inherits a system where every lead is pre-qualified for regulatory fit. For a company operating in the medical device space, where FDA clearance is required, the RevOps leader must build a deal-desk process that flags any prospect whose intended use case falls outside the cleared indications. The sequence is the same but the RevOps leader must have experience with FDA regulatory submissions and 510(k) clearance documentation.

For a company operating in the healthcare analytics space, where data aggregation from multiple sources creates unique privacy risks, the RevOps leader must build a data governance framework that tracks each data source's use restrictions and ensures that sales reps do not promise data sets the company does not have rights to. The sequence is fractional RevOps leader for 9 months to build the data governance infrastructure, then a full-time CRO who can focus on scaling sales without worrying about data compliance. In all cases, the mistake founders make is hiring a CRO first and asking them to build operations from scratch, which delays revenue growth by 6-12 months and increases the risk of a compliance breach that can result in fines of $50,000 to $1.5 million per violation under HIPAA.

FAQ

Should we hire a CRO or RevOps leader first if we have under $10M ARR? At early revenue stages, a RevOps leader typically delivers more immediate impact by building the data infrastructure, process, and CRM hygiene that a future CRO would need. A CRO hired too early often struggles because they lack the operational backbone to execute their strategy. Most founders benefit from first establishing operational rigor, then bringing in a CRO to scale it.

What if we already have inconsistent sales processes and no pipeline visibility? That scenario strongly points to hiring a RevOps leader first. They can standardize deal stages, enforce data discipline, and create reporting that reveals where revenue is stuck. A CRO without that foundation will spend months firefighting instead of driving growth.

Does a CRO hire make sense first if we have a founder-led sales model that is working? It can, but only if the founder is ready to fully delegate revenue ownership and the company has clear, repeatable customer segments. Otherwise, the CRO will clash with the founder’s informal processes, while a RevOps leader could formalize those workflows without disrupting existing momentum.

What is the risk of hiring neither and keeping revenue management with the CEO? The main risk is that the CEO’s attention splits between product, fundraising, and revenue, leading to stalled growth and missed signals from the market. Without a dedicated RevOps or CRO function, data remains anecdotal, and scaling becomes reactive rather than intentional.

Sources